drug
XENON, XE-133
updated 4mo agoby CURIUM
community read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying XENON, XE-133
- N/APulmonary Assessment in Thoracic Insufficiency Syndrome Patients
- phase2Xenon MRI and Progressive ILD
- phase2Lung Functional Avoidance Radiotherapy Using Hyperpolarized Xenon MRI
- phase1Functional Lung Avoidance Radiation Therapy Using Hyperpolarized Xenon-129 MRI
- —Hyperpolarized Xenon Functional Lung Imaging in COPD Patients Undergoing Targeted Lung Denervation
- —Downstream Effects of Airway Mucus Plugs on 129Xenon MRI in Severe Asthma
- phase1Functional and Structural Assessment of Endobronchial Valve Recipients Using Dynamic Hyperpolarized Xenon-129 MRI
- —Assessment of Chronic Lung Allograft Dysfunction Using Single-breath & Multi-breath Hyperpolarized Xenon-129 MRI
News(4)
- SK Biopharma pens $795M deal to usher Biohaven’s epilepsy therapy towards hoped-for 2029 launchSK Biopharmaceuticals has strengthened its epilepsy offering by paying $350 million upfront to help speed Biohaven’s Kv7 ion channel activator on its way to market.fiercebiotech · 23d ago
- EyePoint plummets on pivotal data for main drugThough its drug missed the key goal of a wet AMD study, EyePoint — as well as analysts — see a path toward approval. Investors may be harder to win over, however.biopharma_dive · 1mo ago
- NewLimit’s $435M megaround; Lilly’s busy dealmaking weekThe anti-aging biotech has secured one of the year’s biggest venture fundings to bring its first drug into testing. Elsewhere, Lilly nabbed a “GLP-2” obesity drug and Praxis shares tumbled.biopharma_dive · 3mo ago
- A year after Vertex’s big launch, pain drug research faces a pivotal momentJournavx revived an area of development long considered a graveyard. Can any other pain drugs keep investor excitement going?biopharma_dive · 4mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that